Work

Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177 Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.5020

Authors: Aslı Doğa Munzur, Cameron Herberts, Edmond Michael Kwan, Louise Emmett, Shahneen Sandhu, James Patrick Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Sze Ting Lee, Andrew Mark Scott, Andrew James Martin, Martin R. Stockler, Alison Yan Zhang, Scott G. Williams, Jack V.W. Bacon, Arun Azad, Ian D. Davis, Michael S. Hofman, Alexander William Wyatt, The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Institutions: Vancouver Prostate Centre, Eastern Health, Monash University, St Vincent's Hospital Sydney, Peter MacCallum Cancer Centre, Sir Charles Gairdner Hospital, Austin Health, Olivia Newton-John Cancer Research Institute, The University of Queensland, The University of Sydney

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Australian Nuclear Science and Technology Organisation, Endocyte, Prostate Cancer Foundation of Australia

OpenAlex ID: W4410812239

Cites:

Cited by: 2

Related to: 10